Sign in Create account

Sun Pharma Advanced Research Company Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: SPARC BSE: 532872
₹197.19
▼ -11.66 (-5.58%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
72/100
Strong
Valuation
75/100
Undervalued
Momentum
66/100
Neutral

QVM read Quality at a discount Quality Strong, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹6,399 Cr
PE (TTM)
4.0
Industry median 36.1 (152 companies)
Price to Book
4.8
PEG (TTM)
0.0
Institutions holding %
3.99%
FII + DII, latest filed period
Piotroski Score
7
Relative return vs Nifty50, qtr %
-25.5
Relative return vs Sector, qtr %
-17.0
Free Cash Flow
₹-263 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
59.38%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
627.01%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
2855.80%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
59.68%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
314.11%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
2.47
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.42
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
44.89
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
-52.56%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-32.19%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
84.80%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
71.55%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
112.03%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
116.01%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

5 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • Yes Piotroski F-score is 7 or more (score 7)
  • Yes Debt to equity is below 0.5 (0.42)
  • Yes Return on equity is 15% or more (116.0%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-5.6%
Low 196.0000 · High 210.6500
1W return
-4.1%
Low 196.0000 · High 212.0000
1M return
-1.1%
Low 182.0000 · High 212.0000
52W return
49.2%
Low 108.0000 · High 289.0000
Lifetime High ₹543.6500 (March 9, 2015)
Lifetime Low ₹40.7000 (Dec. 8, 2008)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish1
Bearish5
5D
202.4
10D
201.4
20D
200.6
50D
203.4
100D
198.4
200D
172.7

Delivery and volume

Day avg. delivery
38.9%
Week avg. delivery
40.5%
Month avg. delivery
39.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

201.28
Pivot
First resistance206.56
Second resistance215.93
Third resistance221.21
First support191.91
Second support186.63
Third support177.26
Day RSI46.8
Day MFI59.4
Day MACD0.01
Day MACD signal-1.29

Beta

1M1.87
3M0.95
1Y1.77
3Y1.37

Price change analysis

↓ -1.1%
Over 1 Month
LowHigh
182.00212.00
↓ -17.0%
Over 3 Months
LowHigh
182.00289.00
↑ 63.9%
Over 6 Months
LowHigh
116.12289.00
↑ 49.2%
Over 1 Year
LowHigh
108.00289.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 4.0 (own history: 2.4–4.8)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹40 Cr
Net profit (June 30, 2026)
₹-21 Cr
Basic EPS (June 30, 2026)
₹-0.6500

Ranks #55 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter65.67%
  • Mutual funds0.08%
  • FII/FPI3.90%
  • Other DII0.01%
  • Public30.34%

Largest holders

NameCategoryShares %Shares
Shanghvi Finance Private LimitedPromoter42.2800%137211787
Dilip.S.ShanghviPromoter19.0500%61810660
Sun Pharmaceutical Industries Key Employees Benefit TrustPublic3.1800%10317377
Lakshdeep Investments & Finance (P) Ltd.Public1.8600%6033835
Aditya Medisales LimitedPromoter1.5100%4888126

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 65.67% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 2.47% to 3.90% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 0.09% to 0.08% in Jun 2026 qtr

All shareholding details →

Insider trading, SAST & pledges

All 106 insider trades, 15 SAST, 44 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
24 Feb 2023 SUDHIR V VALIA Promoter group Pledge 0 ₹34.34 Cr
24 Feb 2023 Raksha S Valia Promoter group Pledge 0 ₹41.98 Cr
12 Jan 2023 DILIP SHANTILAL SHANGHVI Promoter Buy 0 ₹0
12 Jan 2023 DILIP SHANTILAL SHANGHVI Promoter Sell 0 ₹0
28 Dec 2022 Raksha S Valia Promoter group Pledge 0 ₹40.62 Cr
5 Dec 2022 Raksha S Valia Promoter group Pledge 0 ₹77.22 Cr
1 Sep 2022 Raksha S Valia Promoter group Pledge 0 ₹22.94 Cr
21 Jun 2022 Raksha S Valia Promoter group Pledge 0 ₹7.49 Cr
20 Jun 2022 Raksha S Valia Promoter group Pledge 0 ₹17.78 Cr
24 May 2022 Raksha S Valia Promoter group Pledge 0 ₹28.19 Cr

All insider and SAST disclosures →

Deals (Bulk & Block)

All 14 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
30 Apr 2026 PSL LIMITED Bulk Sell 2,000,000 148.9100 NSE
4 Dec 2025 IRAGE BROKING SERVICES LLP Bulk Buy 1,151,539 152.4400 BSE
4 Dec 2025 IRAGE BROKING SERVICES LLP Bulk Sell 1,912,360 154.7900 BSE
3 Dec 2025 IRAGE BROKING SERVICES LLP Bulk Buy 2,090,002 166.6300 BSE
3 Dec 2025 IRAGE BROKING SERVICES LLP Bulk Sell 2,641,101 169.2200 BSE
7 Mar 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2,797,403 137.6300 NSE
7 Mar 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 2,797,403 137.5700 NSE
25 Apr 2024 MANSI SHARE AND STOCK ADVISORS PVT LTD Bulk Buy 2,691,489 270.9100 NSE
25 Apr 2024 MANSI SHARE AND STOCK ADVISORS PVT LTD Bulk Sell 1,567,203 272.4300 NSE
19 Sep 2022 ISHARES INDIA SC MAURITIUS COMPANY Block Sell 71,632 221.3000 BSE

All bulk and block deals →

Corporate Actions

Full history (17 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
21 Sep 2021OTHER Annual General Meeting
22 Sep 2020OTHER Annual General Meeting
18 Jul 2019OTHER Annual General Meeting
19 Jul 2018OTHER Annual General Meeting
27 Jul 2017OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
10 Aug 2026 Financial Results Yes
18 May 2026 Financial Results Yes
9 Feb 2026 Financial Results Yes
14 Jan 2026 Fund Raising —
10 Nov 2025 Financial Results Yes

Corporate Announcements

All 635 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
4 Oct 2026 Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company Sun Pharma Advanced Research Company Limited has informed the Exchange about update on Litigation.
25 Sep 2026 Trading Window Sun Pharma Advanced Research Company Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
25 Sep 2026 Insider Trading / SAST Sun Pharma Advanced Research Company Ltd - 532872 - Closure of Trading Window
13 Aug 2026 General Updates Sun Pharma Advanced Research Company Limited has informed the Exchange about Filing of Application for Reclassification with Stock Exchanges
11 Aug 2026 Copy of Newspaper Publication Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication
10 Aug 2026 Shareholders meeting Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 10, 2026
10 Aug 2026 Monitoring Agency Report Sun Pharma Advanced Research Company Limited has informed the Exchange about Monitoring Agency Report for the quarter ended June 30, 2026.
10 Aug 2026 Outcome of Board Meeting Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Outcome of Board Meeting held on August 10, 2026.
10 Aug 2026 Outcome of Board Meeting Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the Unaudited Financial Results for the quarter ended June 30, 2026.
27 Jul 2026 Updates Sun Pharma Advanced Research Company Limited has informed the Exchange about Receipt of requests for reclassification of shareholder category

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • High Return on Equity (116.0%)
  • Comfortable interest coverage (44.9x)
  • Healthy liquidity (Current Ratio 2.47)
  • Strong revenue growth YoY (314.1%)

Weaknesses

  • Thin net profit margin (-52.6%)

Opportunities

  • PEG below 1 (0.01) -- earnings growth outpacing its own valuation
  • PE below 15 (4.0) relative to a typical growth business

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Sun Pharma Advanced Research Company Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.